Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Damora Therapeutics, Inc. (DMRA)

Damora Therapeutics CFO Lori Firmani departs; Brian Burkavage named finance chief

Neutral Impact 4 of 5 leadership Written later

Damora Therapeutics said its Chief Financial Officer, Lori Firmani, ceased serving in that role effective May 1, 2026. Brian Burkavage, the company's Senior Vice President, Finance, was appointed principal financial officer and principal accounting officer at the same time. Firmani's separation benefits are conditional on her signing a separation agreement and general release.

Key points

  • Firmani's departure took effect May 1, 2026; the Board decided on April 28, 2026.
  • Firmani's separation benefits include a $6,000 health savings account contribution and full acceleration of her outstanding equity awards, subject to a release of claims.
  • Burkavage joined Damora in December 2025 and previously served as Senior Vice President, Finance and Chief Accounting Officer at IO Biotech, Inc. from November 2021 to December 2025.

The filing

CompanyDamora Therapeutics, Inc. (DMRA)
Form8-K, current report
Filed with the SECMay 4, 2026, 4:00 PM ET
Accession number0001193125-26-203913

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.